scholarly article | Q13442814 |
P356 | DOI | 10.1086/426398 |
P8608 | Fatcat ID | release_7wu6zgb65je2ljsykebpbkwpg4 |
P698 | PubMed publication ID | 15609237 |
P5875 | ResearchGate publication ID | 8121305 |
P50 | author | Jean-Francois Trape | Q21340358 |
Cheikh Sokhna | Q61809634 | ||
Adama Tall | Q80329231 | ||
Ronald Perraut | Q88302312 | ||
Laurence Marrama | Q94553982 | ||
Shirley Longacre | Q114440098 | ||
P2093 | author name string | Odile Mercereau-Puijalon | |
Pierre Nabeth | |||
Babacar Diouf | |||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Senegal | Q1041 |
malaria | Q12156 | ||
antibody | Q79460 | ||
Plasmodium falciparum | Q311383 | ||
P304 | page(s) | 264-271 | |
P577 | publication date | 2004-12-09 | |
P1433 | published in | Journal of Infectious Diseases | Q4051141 |
P1476 | title | Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese vi | |
P478 | volume | 191 |
Q42581710 | A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. |
Q36625367 | A review of human vaccine research and development: malaria |
Q34955461 | Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response |
Q33380204 | Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum |
Q35739071 | Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children |
Q34334187 | Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum |
Q36393772 | Analysis of antibody profiles in symptomatic malaria in three sentinel sites of Ivory Coast by using multiplex, fluorescent, magnetic, bead-based serological assay (MAGPIX™). |
Q37191417 | Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure |
Q35901099 | Antibodies elicited in adults by a primary Plasmodium falciparum blood-stage infection recognize different epitopes compared with immune individuals |
Q36169093 | Antibodies to Plasmodium falciparum merozoite surface protein-1p19 malaria vaccine candidate induce antibody-dependent respiratory burst in human neutrophils |
Q35010158 | Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines |
Q47996539 | Antibody response to allelic variants of 19kDa fragment of MSP-1: recognition of a variant and protection associated with ethnicity in Assam, India |
Q36800846 | Antibody responses to the merozoite surface protein-1 complex in cerebral malaria patients in India |
Q33380213 | Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults |
Q48035058 | Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development |
Q46471407 | Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria |
Q33927906 | Association of antibody responses to the conserved Plasmodium falciparum merozoite surface protein 5 with protection against clinical malaria |
Q35456892 | Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies |
Q36594057 | Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria |
Q36391845 | Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? |
Q33548663 | Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies |
Q34460065 | Comparative analysis of IgG responses to Plasmodium falciparum MSP1p19 and PF13-DBL1α1 using ELISA and a magnetic bead-based duplex assay (MAGPIX®-Luminex) in a Senegalese meso-endemic community |
Q90300290 | Complement in malaria immunity and vaccines |
Q38089185 | Development of influenza virosome-based synthetic malaria vaccines |
Q37597218 | Diversity and population structure of Plasmodium falciparum in Thailand based on the spatial and temporal haplotype patterns of the C-terminal 19-kDa domain of merozoite surface protein-1 |
Q37684687 | Dramatic declines in seropositivity as determined with crude extracts of Plasmodium falciparum schizonts between 2000 and 2010 in Dielmo and Ndiop, Senegal |
Q34540211 | Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites |
Q37598139 | Hot spot or not: a comparison of spatial statistical methods to predict prospective malaria infections |
Q36838314 | How Should Antibodies against P. falciparum Merozoite Antigens Be Measured? |
Q37382587 | How might infant and paediatric immune responses influence malaria vaccine efficacy? |
Q36123104 | Humoral immune responses to Plasmodium falciparum among HIV-1-infected Kenyan adults |
Q50062994 | Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure |
Q47912581 | IgG responses to candidate malaria vaccine antigens in the urban area of Dakar (Senegal): evolution according to age and parasitemia in patients with mild symptoms |
Q89559305 | Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial |
Q37099503 | Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness |
Q34612788 | Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized |
Q33613892 | In vitro growth-inhibitory activity and malaria risk in a cohort study in mali |
Q36615170 | Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine |
Q33305467 | Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. |
Q36292890 | Longitudinal analysis of antibody responses in symptomatic malaria cases do not mirror parasite transmission in peri-urban area of Cote d'Ivoire between 2010 and 2013. |
Q36219634 | Malaria vaccines in development |
Q33939405 | Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay |
Q31169310 | Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria |
Q58761801 | Optimization of a magnetic bead-based assay (MAGPIX-Luminex) for immune surveillance of exposure to malaria using multiple Plasmodium antigens and sera from different endemic settings |
Q36826951 | Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1. |
Q35532952 | Parasite Specific Antibody Increase Induced by an Episode of Acute P. falciparum Uncomplicated Malaria |
Q39085988 | Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes |
Q35944117 | Plasmodium falciparum line-dependent association of in vitro growth-inhibitory activity and risk of malaria |
Q92664225 | Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort |
Q35762375 | Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies |
Q33510819 | Population diversity and antibody selective pressure to Plasmodium falciparum MSP1 block2 locus in an African malaria-endemic setting |
Q90464578 | Practical example of multiple antibody screening for evaluation of malaria control strategies |
Q33743450 | Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24 |
Q33282524 | Production of high-affinity human monoclonal antibody fab fragments to the 19-kilodalton C-terminal merozoite surface protein 1 of Plasmodium falciparum |
Q46299460 | Profiles of IgG responses against CSP, GLURP and LSA-3NR2 in urban malaria (Dakar): relations with haemoglobin levels and parasite densities |
Q34081745 | Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans |
Q34653470 | Relationship between malaria incidence and IgG levels to Plasmodium falciparum merozoite antigens in Malian children: impact of hemoglobins S and C. |
Q36639261 | Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01. |
Q34189972 | Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic |
Q33793094 | Serological signatures of declining exposure following intensification of integrated malaria control in two rural Senegalese communities |
Q36304234 | Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine |
Q28740432 | T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines |
Q57293070 | Taking Sharper Pictures of Malaria with Combined Antibodies to Measure Exposure Recency Assays |
Q36728063 | Targets and Mechanisms Associated with Protection from Severe Plasmodium falciparum Malaria in Kenyan Children |
Q61799382 | Targets of complement-fixing antibodies in protective immunity against malaria in children |
Q46517899 | The profile of IgG-antibody response against merozoite surface proteins 1 and 2 in severe Plasmodium falciparum malaria in Eastern Sudan |
Q33512926 | The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria |
Q33526349 | The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis |
Q34060022 | Transplacentally transferred functional antibodies against Plasmodium falciparum decrease with age. |
Q47114766 | Unexpected high circulation of Plasmodium vivax in asymptomatic children from Kédougou, southeastern Senegal |
Search more.